Skip to main content

Table 1 Characteristics of studies included in the systematic review by country

From: Immunological markers of Plasmodium vivaxexposure and immunity: a systematic review and meta-analysis

Author, year [reference] Region Age range, years Antibody response (type) Study design (n)a Plasmodium vivaxoutcomeb
Brazil
Fernandez-Becerra, 2010 [22]c Rio Machado DNS PvMSP-1NT, PvMSP-119 (IgG) CS (87) Pv infection (LM or PCR), symptomatic Pv
Kano, 2012 [23] Presidente Figueiredo, Amazonas 9 to 44 PvDBPII-IV, PvMSP-119 (IgG) CS (432) Pv infection (LM or PCR), symptomatic Pv
Lima-Junior, 2008 [24]d Rondonia 10 to 85 PvMSP-9RIRII, PvMSP-9RII, PvMSP-9NT (IgG) CS (282) Pv infection
Lima-Junior, 2011 [25] Rondonia 10 to 81 PvMSP-3αFL, PvMSP-3αNT, PvMSP-3αRI, PvMSP-3αRII, PvMSP-3αCT (IgG) CS (282) Pv infection
Lima-Junior, 2012 [26] Rondonia 11 to 89 PvMSP-119 (IgG) CS (277) Pv infection
Nogueira, 2006 [27] Portuchuelo, Rondonia DNS PvMSP-1NT, PvMSP-119 (IgG) Cohort (173) Pv infection
Oliveira-Ferreira, 2004 [28] Candeias do Jamari, Rondonia 12 to 74 PvCSP (VK210, VK247, P. vivax-like) (IgG) CS (61) Pv infection
Souza-Silva, 2010 [29] Acre 5 to 90 PvDBPII-IV (IgG) Cohort (CS)e (366) Pv infection, Pv infection (LM or PCR)
Tran, 2005 [30]f Colina and Ribeirinha, Rondonia 11 to 75 PvRBP1 (IgG) CS (87) Pv infection
Versiani, 2013 [31] Rio Pardo DNS PvMSP-1NT (IgG, IgG1, IgG2, IgG3, IgG4) Cohort (CS)e (308) Pv infection, symptomatic Pv
Indonesia
Ak, 1998 [32] Robek 0 to 73 PvMSP-119 (IgG + IgM) CS (169) Pv infection
Woodberry, 2008 [33] Timika, Papua 3 to 60 PvMSP-5 (IgG, IgM, IgG1, IgG2, IgG3, IgG4) CC (340) Symptomatic Pv
Papua New Guinea
Cole-Tobian, 2009 [34] Madang 5 to 14 PvDBPII (AH, O, P, Sal 1), PvMSP-119 (IgG) Cohortg (206) Pv infection, Pv infection (LDR-FMA), Pv infection >150 parasites/μl
Fernandez-Becerra, 2010 [22] Madang 0.25 to 3 PvMSP-1NT, PvMSP-119 (IgG) CS (100) Pv infection (LM or PCR), symptomatic Pv
King, 2008 [35] Madang 5 to 14 PvDBPII binding inhibitory antibodies Cohort (206)h Pv infection
Stanisic, 2013 [36] East Sepik 0.9 to 3.1 PvMSP-3αNT, PvMSP-3αRI, PvMSP-3αRII, PvMSP-3αCT, PvMSP-9NT, PvMSP-9RIRII (IgG) Cohort (CS)e (183) Pv infection (LDR-FMA), symptomatic Pv
Thailand
Fowkes, 2012 [37] Mae Sot, Tak 15 to 42i PvAMA1-ecto (IgG) Nested CC (467) Pv infection
Wongsrichanalai, 1991 [38] Chanthaburi DNS PvCSP (VK210) (IgG) CC (126) Pv infection
Turkey
Yildiz Zeyrek, 2011 [39] Sanliurfa 0 to 77 PvMSP-119, PvAMA1-ecto, PvSERA4, PvCSP (VK210 and VK247 chimera) (IgG, IgM, IgG1, IgG2, IgG3, IgG4) CS (195) Pv infection
  1. CC, case-control; CS, cross-sectional; DNS, did not state; LDR-FMA, ligase detection reaction-fluorescent microsphere assay; LM, light microscopy; PV, Plasmodium vivax.
  2. aSample size refers to number of participants for whom serology was determined.
  3. b P. vivax infection was determined by light microscopy unless otherwise stated.
  4. cFernandez-Becerra, 2010 [22] reported studies performed in two countries and features twice in Table 1.
  5. dThe studies described by Lima-Junior in 2008 and 2012 [24],[26] were conducted in the same area, but the participants were different.
  6. eCohort study with cross-sectional data also included.
  7. fTran, 2005 [30] included data from two different study sites in Brazil.
  8. gTreatment to re-infection study.
  9. hKing, 2008 [35] reported estimates from the same treatment to re-infection study as that described by Cole-Tobian, 2009 [34].
  10. iThis study comprised pregnant women.
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us